文献速递白血病

KDM6去甲基化酶整合DNA修复基因调控,KDM6A缺失使人类急性髓系白血病对PARP和BCL2抑制敏感

KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
PubMed 文献 · Leukemia · 2023-01-31

本研究探讨KDM6去甲基化酶在急性髓系白血病(AML)中对DNA损伤修复(DDR)基因表达的调控作用。KDM6A/B缺失损害DDR转录激活和修复潜能,KDM6A缺失增加线粒体活性和BCL2表达并使AML细胞对维奈克拉敏感,PARP和BCL2双靶向优于单药诱导AML凋亡,携带KDM6A结构域突变的原代AML细胞对联合治疗更敏感。

要点

  • KDM6A/B缺失损害AML细胞DDR转录激活和修复潜能
  • KDM6A缺失增加线粒体活性和BCL2表达,使AML细胞对维奈克拉敏感
  • PARP和BCL2双靶向优于单药,KDM6A结构域突变原代AML细胞对联合更敏感

核心结论

  • KDM6去甲基化酶功能关键调控AML中DNA损伤修复基因表达,KDM6A可作为决定治疗疗效的分子调节因子。
  • 基于亚型异质性,研究提供了一种新型联合治疗方案的机制依据。

研究设计与样本

  • 研究为实验室研究,涉及AML细胞、患者来源异种移植模型和原代AML细胞。

主要发现

  • KDM6表达受基因毒性应激调控,KDM6A(UTX)和KDM6B(JMJD3)缺失损害DDR转录激活和修复潜能。
  • 获得性KDM6A功能缺失突变与化疗耐药相关,但相当比例复发AML中KDM6A上调。
  • 奥拉帕利治疗减少KDM6A突变AML患者来源异种移植物的植入。
  • 较高的KDM6A表达与维奈克拉耐受相关;KDM6A缺失增加线粒体活性、BCL2表达并使AML细胞对维奈克拉敏感。
  • BCL2A1与维奈克拉耐药相关,KDM6A缺失伴随BCL2A1下调;PARP和BCL2双靶向在诱导AML凋亡方面优于PARP或BCL2抑制剂单药,携带KDM6A结构域突变的原代AML细胞对联合治疗更敏感。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a heterogeneous, aggressive malignancy with dismal prognosis and with limited availability of targeted therapies. Epigenetic deregulation contributes to AML pathogenesis. KDM6 proteins are histone-3-lysine-27-demethylases that play context-dependent roles in AML. We inform that KDM6-demethylase function critically regulates DNA-damage-repair-(DDR) gene expression in AML. Mechanistically, KDM6 expression is regulated by genotoxic stress, with deficiency of KDM6A-(UTX) and KDM6B-(JMJD3) impairing DDR transcriptional activation and compromising repair potential. Acquired KDM6A loss-of-function mutations are implicated in chemoresistance, although a significant percentage of relapsed-AML has upregulated KDM6A. Olaparib treatment reduced engraftment of KDM6A-mutant-AML-patient-derived xenografts, highlighting synthetic lethality using Poly-(ADP-ribose)-polymerase-(PARP)-inhibition. Crucially, a higher KDM6A expression is correlated with venetoclax tolerance. Loss of KDM6A increased mitochondrial activity, BCL2 expression, and sensitized AML cells to venetoclax. Additionally, BCL2A1 associates with venetoclax resistance, and KDM6A loss was accompanied with a downregulated BCL2A1. Corroborating these results, dual targeting of PARP and BCL2 was superior to PARP or BCL2 inhibitor monotherapy in inducing AML apoptosis, and primary AML cells carrying KDM6A-domain mutations were even more sensitive to the combination. Together, our study illustrates a mechanistic rationale in support of a novel combination therapy for AML based on subtype-heterogeneity, and establishes KDM6A as a molecular regulator for determining therapeutic efficacy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Boila LD, Ghosh S, Bandyopadhyay SK, et al. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia. 2023. PMID: 36720973. doi:10.1038/s41375-023-01833-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。